KMT2A and acute myeloid leukemia: Pre-clinical data indicate that ATRA treatment in MLL::AF9 rearranged AML cells effectively induces differentiation by upregulating transcription factors such as RARA, CCAAT/enhancer protein alpha (CEBP-alpha), or PU.1.